What’s Next? Five Things To Look Out For In July
Viatris May Bag Landmark FDA Interchangeable Approvals
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
You may also be interested in...
Program aims to share rebate savings from preferred drugs, ease treatment disruptions. Products like Remicade covered under medical benefits require new kinds of incentives for switching.
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.
With a looming entry deadline of 30 July, companies have a little under two months to enter the Global Generics & Biosimilars Awards 2021, ahead of the awards ceremony on 10 November.